working

Sign up for free to access

Get access to the latest equity research in real-time from 12 commissioned providers.

Get access to the latest equity research in real-time from 12 commissioned providers.


Get Started
Already a member? Log in here

More Content

More Content

MTVA: DA-1241 in Combination with Efruxifermin Shows Additive Hepatoprotective Effects in Mouse MASH Model

Companies: MetaVia Inc.

NRBO: Preclinical Data on DA-1241 with Semaglutide to be Presented at EASL Congress 2024

Companies: NeuroBo Pharmaceuticals Inc (NRBO:NYSE)MetaVia Inc. (MTVA:NAS)

MTVA: Additional Positive Topline Results for DA-1726 in Phase 1 MAD Study

Companies: MetaVia Inc.

NRBO: Data from Part 1 of Phase 1 Trial of DA-1726 in 3Q24

Companies: NeuroBo Pharmaceuticals Inc (NRBO:NYSE)MetaVia Inc. (MTVA:NAS)

MTVA: Positive Phase 1 MAD Data for DA-1726 Excellent Tolerability Profile and Mean Day 26 Weight Loss of 4.3%

Companies: MetaVia Inc.

© Research Tree 2025

  • Apple Store
  • Play Store

Research Tree will never share your details with third parties for marketing purposes. Research Tree distributes research documents that have been produced and approved by Financial Conduct Authority (FCA) Authorised & Regulated firms as well as relevant content from non-authorised sources, who are not regulated but the information is in the public domain. For the avoidance of doubt Research Tree is not giving advice, nor has Research Tree validated any of the information.

Research Tree is an Appointed Representative of Sturgeon Ventures which is Authorised and Regulated by the Financial Conduct Authority.

Top